Conditions: Uterine Sarcoma; Uterine Leiomyosarcoma; Endometrial Stromal Sarcoma; ESS; Perivascular Epithelioid Cell Tumors; Uterine Adenosarcoma; Uterine PEComa; Estrogen Receptor Positive Tumor; uLMS
Interventions: Drug: Elacestrant
Sponsors: Dana-Farber Cancer Institute; Stemline Therapeutics, Inc.
Not yet **RECRUITING NOW**
Interventions: Drug: Elacestrant
Sponsors: Dana-Farber Cancer Institute; Stemline Therapeutics, Inc.
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
